By Léon Van Wouwe, Clinical Innovation Director, Volv Global Recently, I had powerful thought come to me on reading…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Gastric (stomach) cancer remains a formidable global health challenge, ranking…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…
By Christopher Rudolf, Volv Global An AI Methodology for Finding Patients with Rare Diseases: Volv Global’s inTrigue Finding patients with…
Volv, supported by Sanofi, and working with Optimum Patient Care, and collaborating with a specialist Consultant Clinician, is performing research…
By Volv Global SA and WODC EU contributors Executive Summary For decades, the pharmaceutical industry has faced the same…
By Christopher Rudolf, Volv Global Rare disease patients and the journey to diagnosis, treatment, and support For patients with rare…